Literature DB >> 23504537

The routine use of atypical cultures in presumed aseptic revisions is unnecessary.

Anthony T Tokarski1, Joseph O'Neil, Carl A Deirmengian, Joseph Ferguson, Gregory K Deirmengian.   

Abstract

BACKGROUND: In presumed aseptic hip and knee revisions, it is common practice to send intraoperative cultures to screen for occult infection. Currently no guidelines exist for the routine use of acid-fast bacillus (AFB) and fungal cultures in this setting. QUESTIONS/PURPOSES: We established (1) the rate of positive fungal and AFB cultures in aseptic hip and knee revision arthroplasties, (2) factors associated with positive fungal and AFB cultures, (3) the likelihood that positive cultures represent true-positive results, and (4) the hospital charges of sending fungal and AFB cultures routinely.
METHODS: We retrospectively evaluated all 1717 presumed aseptic hip and knee revisions performed from January 2006 to November 2011: 1139 patients had at least one intraoperative fungal culture and 1133 patients had at least one intraoperative AFB culture, with 923 and 920, respectively, achieving 1-year followup. The Musculoskeletal Infection Society criteria were used to classify subsequent infections. We attempted to identify risk factors for positive cultures.
RESULTS: We observed six (0.5%) patients with positive AFB cultures and 19 (1.7%) with positive fungal cultures. Patients undergoing reimplantation procedures were more likely to have a positive fungal culture. The true-positive rate was 0% and 0.1% for AFB and fungal cultures, respectively. The total hospital charges for these cultures over the time frame of our study were USD 1,315,533.
CONCLUSIONS: Given the extremely low rate of true-positive AFB and fungal cultures in presumed aseptic revision joint arthroplasty and the charges associated with maintaining these cultures, we believe their routine use is unwarranted. LEVEL OF EVIDENCE: Level III, prognostic study. See the Instructions for Authors for a complete description of evidence.

Entities:  

Mesh:

Year:  2013        PMID: 23504537      PMCID: PMC3773133          DOI: 10.1007/s11999-013-2917-7

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  21 in total

1.  New definition for periprosthetic joint infection.

Authors:  Javad Parvizi
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2011-12

Review 2.  Management and prevention of prosthetic joint infection.

Authors:  Emily K Shuman; Andrew Urquhart; Preeti N Malani
Journal:  Infect Dis Clin North Am       Date:  2012-03       Impact factor: 5.982

3.  Definition of periprosthetic joint infection: is there a consensus?

Authors:  Javad Parvizi; Christina Jacovides; Benjamin Zmistowski; Kwang Am Jung
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

4.  Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience.

Authors:  Khalid Azzam; Javad Parvizi; Donald Jungkind; Arlen Hanssen; Thomas Fehring; Bryan Springer; Kevin Bozic; Craig Della Valle; Luis Pulido; Robert Barrack
Journal:  J Bone Joint Surg Am       Date:  2009-11       Impact factor: 5.284

5.  Use and cost-effectiveness of intraoperative acid-fast bacilli and fungal cultures in assessing infection of joint arthroplasties.

Authors:  Veronica M Wadey; James I Huddleston; Stuart B Goodman; David J Schurman; William J Maloney; Ellen J Baron
Journal:  J Arthroplasty       Date:  2009-10-30       Impact factor: 4.757

Review 6.  Preoperative diagnosis of periprosthetic joint infection: role of aspiration.

Authors:  Matthew W Squire; Craig J Della Valle; Javad Parvizi
Journal:  AJR Am J Roentgenol       Date:  2011-04       Impact factor: 3.959

7.  Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections.

Authors:  H Segawa; D T Tsukayama; R F Kyle; D A Becker; R B Gustilo
Journal:  J Bone Joint Surg Am       Date:  1999-10       Impact factor: 5.284

8.  Aseptic loosening of total hip arthroplasty: infection always should be ruled out.

Authors:  Javad Parvizi; Dong-Hun Suh; S Mehdi Jafari; Adam Mullan; James J Purtill
Journal:  Clin Orthop Relat Res       Date:  2011-03-02       Impact factor: 4.176

9.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

10.  Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey.

Authors:  Alexia Cusini; Silvana K Rampini; Vineeta Bansal; Bruno Ledergerber; Stefan P Kuster; Christian Ruef; Rainer Weber
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more
  5 in total

1.  Infection post-total knee replacement: current concepts.

Authors:  Pouya Alijanipour; Javad Parvizi
Journal:  Curr Rev Musculoskelet Med       Date:  2014-06

2.  Management of Resistant, Atypical and Culture-negative Periprosthetic Joint Infections after Hip and Knee Arthroplasty.

Authors:  Alexander S McLawhorn; Danyal H Nawabi; Amar S Ranawat
Journal:  Open Orthop J       Date:  2016-11-30

3.  Eradicating Fungal Periprosthetic TKA "Super-infection": Review of the Contemporary Literature and Consideration of Antibiotic-Impregnated Dissolving Calcium Sulfate Beads as a Novel PJI Treatment Adjunct.

Authors:  Andrew P Kurmis
Journal:  Arthroplast Today       Date:  2021-03-25

4.  The Utility of Acid-Fast Bacillus (AFB) and Fungal Cultures in Orthopaedic Infections.

Authors:  Jared Sanderford; Jacqueline Krumrey; Erin Campaigniac; Jason Lin; Peter Tsai; Olivia Pipitone
Journal:  Cureus       Date:  2022-07-07

5.  Is It Cost Effective to Obtain Fungal and Acid-Fast Bacillus Cultures during Spine Debridement?

Authors:  Mark J Lambrechts; Devin D St Clair; Jinpu Li; James L Cook; Bradley S Spence; Emily V Leary; Theodore J Choma; Donald K Moore; Christina L Goldstein
Journal:  Asian Spine J       Date:  2021-11-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.